AstraZeneca (AZN) stock is performing well but is facing some difficulty due to vaccine reactions and shares lost -1.63% to close Wednesday’s session at $48.42. but it is in positive mode and has gained 3.22% to trade at $49.98 in Thursday premarket at last check. Over the past three months, the stock has lost -4.50%, while over the past six months, it has shed -11.14%.
Unchanged age limit for AstraZeneca COVID shot in Germany
On April 8, 2021, Germany’s vaccine regulator said that it is not going to change the age limit for AstraZeneca’s COVID-19 vaccine and it will still be given to those aged over 60.
On April 7, 2021, The European Union’s drug regulator allows individual countries on how to handle the risk of rare blood clots from AstraZeneca’s COVID-19 vaccine.
Africa wants Johnson & Johnson vaccine instead of AstraZeneca
On April 8, 2021, The African Union dismissed its plan to buy COVID-19 vaccines from the Serum Institute of India and now looking to buy additional vaccine from Johnson & Johnson.
Africa is already getting the supply of AstraZeneca through the COVAX vaccine-sharing facility but a recent surge forced them to get more vaccine.
The recent decision came after European and British medicine regulators said they had found possible links between AstraZeneca’s vaccine and reports of very rare cases of brain blood clots.
Australia still getting AstraZeneca vaccine despite an import ban
On April 8, 2021, another batch of AstraZeneca vaccine has been sent to Australia from Britain but the source of the shipments was kept quiet
Another shipment arrived on an Emirates passenger plane in March well after when the European regulator blocked the AstraZeneca application to ship 250,000 doses to Australia.
The first 300,000 AstraZeneca vaccine doses landed at Sydney airport on February 28.
AstraZeneca stock was a hot cake for investors in recent months after its start producing vaccine to fight COVID-19. But its vaccine is facing some problem such as rare blood clots which is the most common reaction. The AZN stock which soared rapidly now facing some difficulty due to vaccine reactions and coming down as more and more countries are reviewing their decisions to buy the AstraZeneca vaccine.